Starpharma Holdings Limited (ASX: SPL) - ETF Exposure
- Current share price for SPL : $0.715
Starpharma Holdings Limited (SPL) is an ASX-listed company and is held by a number of exchange traded funds (ETFs). It is a biotechnology company with over 20 years of experience in developing dendrimer technology for pharmaceutical applications. Their mission is to help patients with significant illnesses, such as cancer, achieve improved health outcomes and quality of life through the application of their unique dendrimer technology.
SPL General Information +
| ASX Code | SPL |
| Website | N/A |
| Industry/Sector | Pharmaceuticals |
| Market Cap ($M) | 341 |
| SPL Share Price | $0.715 |
| Day High | $0.725 |
| Day Low | $0.715 |
| Last Close | $0.715 |
| SPL Share Price Movement | - ( No change ) |
Prices as at 16:40, 28 Aug 2026
+Security prices are delayed by at least 20 minutes and are indicative only.
Starpharma Holdings Limited (SPL) Upcoming Dividends & Yields
| Distribution Type | Dividend | Franking | Ex-dividend date | Payment date | Current Price+ | Price 7D Avg | Dividend Yield |
|---|---|---|---|---|---|---|---|
| Interim | 1.5¢ | 100% | 25 Mar 1988 | 15 Apr 1988 | - | - | - |
See all dividends from Starpharma Holdings Limited (SPL) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.
Starpharma Holdings Limited (SPL) price-sensitive announcements
SPL - FY26 Key Financial Results and Annual Report
Starpharma Holdings Limited, an innovative biotechnology company specializing in dendrimer
Starpharma Holdings Limited (SPL)
26 Aug 2026 | 9:45 AM
26 Aug 2026 | 9:45 AM
SPL - Preliminary Final Report
Starpharma Holdings Limited's Preliminary Financial Report for the year ended 30 June 2026
Starpharma Holdings Limited (SPL)
26 Aug 2026 | 9:23 AM
26 Aug 2026 | 9:23 AM
SPL - Successful Completion of $32 million Entitlement Offer
Starpharma Holdings Limited announced the successful completion of a $32 million Entitleme
Starpharma Holdings Limited (SPL)
11 Aug 2026 | 9:49 AM
11 Aug 2026 | 9:49 AM
SPL - Entitlement Offer Investor Presentation
Starpharma Holdings Limited is launching a fully underwritten approximately A$32 million p
Starpharma Holdings Limited (SPL)
15 Jul 2026 | 9:15 AM
15 Jul 2026 | 9:15 AM
Starpharma Holdings Limited (SPL) Recent ASX Announcements
SPL Financial Summary
| Year to Jun | NPAT | EPS | EPS chg (%) | PER | DPS | Yield (%) | Franking (%) |
|---|---|---|---|---|---|---|---|
| 2026A | -$7.47 | -$1.70 | -25.80% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2025A | -$9.99 | -$2.30 | 20.70% | 0.00 | 0.00 | 0.00% | 0.0% |
| 2024A | -$8.17 | -$1.90 | -48.10% | 0.00 | 0.00 | 0.00% | 0.0% |
SPL Peer Comparison
| Company | Mkt Cap | EPS Growth (%) | P/E (%) | Dividend Yield (%) | ||||||
|---|---|---|---|---|---|---|---|---|---|---|
| 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | 2024 A | 2025 A | 2026 A | ||
| Clarity Pharmaceuticals Ltd (CU6) | $873M | 0.3002 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
| Neuren Pharmaceuticals Limited (NEU) | $2,665M | -0.7857 | 0.2462 | 0.9655 | 90.3309 | 72.4828 | 36.8772 | 0.00% | 1.57% | 1.86% |
| Starpharma Holdings Limited (SPL) | $341M | -0.2575 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.00% | 0.00% | 0.00% |
SPL Directors
| Name | Position | Start Date |
|---|---|---|
| Ms Cheryl Ann Maley | Chief Executive Officer, Managing Director | 8 Jan 2024 |
| Mr David McIntyre | Non-Executive Director | 1 Mar 2020 |
| Ms Lynda Cheng | Non-Executive Director | 1 Aug 2021 |
| Dr Jeff Davies | Non-Executive Director | 1 Apr 2022 |
| Dr Russell Basser | Non-Executive Director | 20 Feb 2023 |
| Mr Robert Bain Thomas | Non-Executive Director, Non-Executive Chairman | 4 Dec 2013 |
Starpharma Holdings Limited (SPL) Changes in Directors' Interest & Trades
| Date of change | Director | Buy/Sell | Security Type | Qty | Trade Price | Value |
|---|---|---|---|---|---|---|
| 11 Aug 2026 | DAVIES, Jeff | Issued | Indirect Shares | 117,291 | $0.570 | $66,856.000 |
| 11 Aug 2026 | BASSER, Russell | Issued | Direct Shares | 36,191 | $0.570 | $20,629.000 |
| 11 Aug 2026 | CHENG, Lynda | Issued | Indirect Shares | 22,741 | $0.570 | $12,962.000 |
See all changes in directors' interest & trades for Starpharma Holdings Limited (SPL) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.
SPL Management
| Name | Position |
|---|---|
| Justin Cahill | Chief Financial Officer,Company Secretary |
SPL Substantial Shareholders
Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Starpharma Holdings Limited (SPL). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.
| Holding | Name |
|---|---|
| 48,480,000 (11.80%) | Allianz SE and the entities |
| 29,838,184 (7.10%) | Robmar Investments Pty Umited |
| 26,680,974 (6.40%) | ICM Investment Management Ltd |
SPL Calendar of Events
| Date | Event |
|---|---|
| 25 August 2027 | Report (Annual) |
| 25 August 2027 | Report (Prelim) |
| 17 February 2027 | Report (Interim) |
DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.
Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate,
complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892)
and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and,
if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest.
No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser.
Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.
What our members say about us
Proudly
We're here to help
Call 1300 880 160
Start a chat
Schedule a call
